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2018 EVD Outbreak, Eastern DRC
 August 1, 2018, Ministry of 
Health confirmed an outbreak 
of Ebola virus disease (EVD) in 
North Kivu Province in Eastern 
Democratic Republic of Congo
 Zaire ebolavirus species
 10th EVD outbreak in DRC, 
largest to ever have occurred 
there
Case Counts as of September 29, 2019
 Cases reported in 29 
health zones; 3 provinces
 >3000 cases; >2000 
deaths
 165 healthcare workers 
infected 
Background
 Ebola virus disease (EVD) is a deadly disease caused by infection with 
one of 4 viruses within the genus Ebolavirus, family Filoviridae
–
–
–
–
Ebola virus (species Zaire ebolavirus)
Sudan virus (species Sudan ebolavirus)
Tai Forest virus (species Tai Forest ebolavirus)
Bundibugyo virus (species Bundibugyo ebolavirus)
 Natural reservoir unknown; likely bats
Background (continued)
 Ebola virus disease (EVD) is a deadly disease caused by infection with 
one of 4 viruses within the genus Ebolavirus, family Filoviridae
–
–
–
–
Ebola virus (species Zaire ebolavirus)
Sudan virus (species Sudan ebolavirus)
Tai Forest virus (species Tai Forest ebolavirus)
Bundibugyo virus (species Bundibugyo ebolavirus)
Ebola virus (species Zaire ebolavirus)
 Responsible for 18/28 (64%) of 
EVD outbreaks reported since 1976
• 31,059 cases; 12,970 deaths*
 Two largest EVD outbreaks due to 
Ebola virus
• 2014 West Africa outbreak
• Current DRC outbreak
 Untreated, mortality rates 70-90%
• Highest mortality rate amongst the 
4 viruses within genus
*not including current DRC outbreak
Person-to-Person Transmission
 Ebola virus can be found in all body fluids:
–
–
–
–
–
–
–
–
–
–
Blood
Feces/vomit
Urine
Tears
Saliva
Breast milk
Amniotic fluids
Vaginal secretions
Sweat
Semen
 Contact (through a break in skin, mouth, eyes, mucous membranes) with 
the body fluids of a person that is sick or has died of EVD.
Signs and Symptoms
 Signs and symptoms of EVD include:
–
–
–
–
–
–
–
–
–
Fever
Headache
Fatigue
Muscle pain/joint pain
Bleeding (epistaxis, injection sites)
Abdominal pain
Rash
Diarrhea
Vomiting
 A person infected with Ebola virus is not contagious until symptoms 
appear
Progression of EVD
 Wet symptoms develop ~ day 4 
of illness
 Patient becomes increasingly 
contagious as the illness 
advances
 Without treatment, death 
usually occurs 7-10 days after 
illness onset
 Concentration of Ebola virus in 
the body is highest at the time 
of death
EVD Sequalae
 Incidence of sequalae amongst EVD survivors unknown
 Sequalae vary over time; most resolve over time
 Most commonly reported signs/symptoms: 
–
–
6 mo: Arthralgia, myalgia, abdominal pain, fatigue1
2 yr: uveitis, headache, joint pain, cataracts, muscle pain2
 Within one year of discharge, Ebola survivors had 5-fold greater 
mortality than the general population3
 Ebola virus persistence in immunoprivileged sites (e.g., testes, eyes, 
brain, placenta)
1. Rowe et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of Congo
2. Prevail III Study Group. A longitudinal study of Ebola sequelae in Liberia
3. Keita et al. Subsequent mortality in survivors of Ebola virus disease in Guinea: a nationwide retrospective cohort study Lancet Infect Dis. 2019
Immunity
 Duration of natural immunity against Ebola virus in survivors unknown
–
–
Survivor found to have high levels of specific IgG antibodies to Ebola 
virus glycoprotein and neutralizing activity at 11 years1 and 40 years 
after recovery2 
Natural immunity postulated to be species specific
 Immune correlate for protection in humans against Ebola virus infection 
is unknown
 Protection due to a combination of humoral and cell-mediated immunity
1 Corti et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
2 Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire outbreak 40 years after infection
Treatment
 No FDA-approved treatments for EVD
 Early supportive care alone can significantly improve chances of survival 
~40%
 In a randomized clinical control trial in DRC, Regeneron and mAB114 
were found to reduce mortality to 29% - 34% respectively 
Ebola Virus Disease in the United States
 11 individuals treated for EVD in the United States
–
–
–
–
–
All associated with 2014-2016 West Africa EVD outbreak
7/11: EVD diagnosed overseas, medically evacuated to the United 
States for care
4/11: EVD diagnosis made in the United States
2/11 (18%) died
 1 imported case of EVD generated 2 secondary cases in the U.S. 
Both secondary cases were nurses
Ebola Virus Disease in the United States (Continued)
 11 EVD patients treated at five hospitals in the United States
 8/11 treatment initiated at Special Pathogen Treatment Centers (Emory, 
Nebraska, NIH, Bellevue)
 3/11 initially treated at community hospital; later transferred to special 
pathogen treatment centers 
Populations at Risk for EVD in the United States
 Laboratory personnel who directly handle cultures/diagnostic 
samples/animals contaminated or infected with replication-competent 
Ebola virus 
 Healthcare workers at U.S. Special Pathogen Treatment Centers caring 
for an EVD patient
 Personnel responding to an EVD outbreak
Biosafety Level 4 (BSL-4) Laboratory Personnel
 BLS-4 laboratories in the U.S ~350-400 lab and support staff
 Individuals who handle cultures/animals contaminated or infected with 
replication-competent Ebola virus for research purposes
 Individuals who handle diagnostic or clinical specimens containing replication-
competent Ebola virus 
CDC, GA Galveston National Laboratory, TX
Georgia State, GA Shope Laboratory, TX
NIH, MD Texas Biomedical Research Institute, TX
USAMRIID, MD Rocky Mountain Laboratories, MO
National Emerging Infectious Disease, MA National Biodefense Analysis and 
Countermeasures Center, MD
Laboratory Response Network Personnel
 Composed of local, state, federal public health, food testing, 
veterinary diagnostic, and environmental testing 
laboratories
 Affiliated with federal agencies, military installations, 
international partners, state/local public health departments
 57 LRN labs have the capacity to test for Ebola virus
• 37 labs have tested clinical samples collected from suspect EVD 
patients in the United States
Regional Treatment Network
 Developed in response to US EVD cases during 2014 West Africa Outbreak
 Nationwide regional treatment network for Ebola and other special 
pathogens
Type Number Role
Frontline healthcare facilities 4845 Has necessary materials/staff to care for 
suspect/confirmed EVD patient for at least 12 -24 
hours
Ebola Assessment Hospital 217 Has necessary materials/staff to care for 
suspect/confirmed EVD patient for up to 96 hours
Ebola Treatment Center 63 Has necessary materials/staff to care for 
suspect/confirmed EVD patient for up to 7 days.
Regional Special Pathogen 
Center
10 Able to treat simultaneously at least two patients 
with Ebola for duration of illness
Special Pathogen Treatment Center Personnel
 10 regional Special Pathogens Treatment Centers in the U.S. ~ 500 healthcare 
workers/support staff
 Specialized high-level isolation units equipped with infrastructure, laboratory 
capabilities, staff to care for patients with highly hazardous communicable diseases 
 Able to treat simultaneously at least two patients with Ebola for duration of illness
https://netec.org/regional-resource-map/
Persons Responding to EVD Outbreaks
 Number of organizations responding to an outbreak will vary by size and 
location of the outbreak
 > 4,000 U.S. government personnel deployed to 2014 West Africa EVD 
outbreak (including domestic EVD cases)
1 https://www.cdc.gov/mmwr/volumes/65/su/pdfs/su6503.pdf 3 https://archive.defense.gov/news/newsarticle.aspx?id=123935
4Update on the U.S.Public Health Response to the Ebola Outbreak
Recombinant Vesicular Stomatitis Virus-Based Ebola 
Virus Vaccine (rVSVΔG-ZEBOV-GP )
 Live-attenuated recombinant vesicular 
stomatitis virus vaccine
 Initially developed by Public Health Agency 
Canada and New Link Genetics 
 Merck currently holds intellectual rights
Vaccination Strategy Eastern DRC EVD Outbreak
Ring Vaccination Strategy
WHO
Summary Slide
 Ebola virus (species Zaire ebolavirus) infection causes a severe disease 
with high morbidity and mortality
 Ebola virus responsible for 64% of EVD outbreaks; >31,000 infected; 
>12,000 deaths
 Current outbreak is the largest in DRC and is still ongoing
 US personnel at risk for occupational exposure
–
–
–
Laboratory personnel
Healthcare personnel at Special Pathogen Treatment Centers
Persons responding to EVD outbreaks
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
